Key result
Whole genome sequencing identifies a novel PRKAR1A deletion causing Carney complex after 10 years of negative testing.
Why the study?
Genetic alterations causing Carney complex are often missed under routine genetic testing, leaving causal variants unidentified in some kindreds.
Does whole genome sequencing identify the causal genetic alteration in patients with Carney complex where conventional genetic analysis fails?
Case Report (n=4)
No
Does whole genome sequencing identify the causal genetic alteration in patients with Carney complex where conventional genetic analysis fails?
Whole genome sequencing can successfully identify pathogenic structural variants in non-coding regions, such as promoter deletions, in patients with Carney complex when conventional targeted and exome sequencing fail.
May support WGS in unresolved Carney complex cases; leaves open broader adoption pending validation studies.
Carney complex (CNC) is an ultrarare disorder causing cutaneous and cardiac myxomas, primary pigmented nodular adrenocortical disease, hypophyseal adenoma, and gonadal tumours. Genetic alterations are often missed under routine genetic testing. Pathogenic variants in PRKAR1A are identified in most cases, while large exonic or chromosomal deletions have only been reported in a few cases. Our aim was to identify the causal genetic alteration in our kindred with a clinical diagnosis of CNC and prove its pathogenic role by functional investigation. Targeted testing of PRKAR1A gene, whole exome and whole genome sequencing (WGS) were performed in the proband, one clinically affected and one unaffected relative. WGS identified a novel, large, 10,662 bp (10.6 kbp; LRG_514t1:c.-10403_-7 + 265del; hg19, chr17:g.66498293_66508954del) deletion in the promoter of PRKAR1A in heterozygous form in the affected family members. The exact breakpoints and the increased enzyme activity in deletion carriers compared to wild type carrier were proved. Segregation analysis and functional evaluation of PKA activity confirmed the pathogenic role of this alteration. A novel deletion upstream of the PRKAR1A gene was proved to be the cause of CNC. Our study underlines the need for WGS in molecular genetic testing of patients with monogenic disorders where conventional genetic analysis fails.
No takes yet. Share an insight, caveat, or question.
Pálla et al. (2023) conducted a case report in Carney complex (n=4). Whole genome sequencing vs. Routine genetic testing (targeted sequencing and WES) was evaluated on Identification of pathogenic genetic variant. Whole genome sequencing identified a novel 10.6 kb deletion in the PRKAR1A promoter as the cause of Carney complex in a family after 10 years of negative routine genetic testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: